Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
198
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets

Murari Ramesha Sydney Medical School, The University of Sydney, Camperdown, AustraliaView further author information
,
James Favalorob The Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, AustraliaView further author information
,
Christian Bryanta Sydney Medical School, The University of Sydney, Camperdown, Australia;b The Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, AustraliaView further author information
,
Phoebe Joy Hoa Sydney Medical School, The University of Sydney, Camperdown, Australia;b The Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, AustraliaView further author information
&
Edward Abadira Sydney Medical School, The University of Sydney, Camperdown, Australia;b The Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4152-5079View further author information
ORCID Icon
Pages 2005-2009 | Received 30 Oct 2020, Accepted 30 Jan 2021, Published online: 20 Feb 2021

References

  • Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317–2332.
  • Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52.
  • Perna F, Berman SH, Soni RK, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32(4):506–519.
  • Drent E, Groen RWJ, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616–625.
  • Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer. 2018;65(4):e26914.
  • Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–2060.
  • Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–2784.
  • Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
  • Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:eaau7746.
  • Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematol Am Soc Hematol Educ Progr. 2020;2020(1):264–271.
  • Romero X, Benítez D, March S, et al. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens. 2004;64(2):132–144.
  • Radhakrishnan SV, Luetkens T, Scherer SD, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020;11(1):1–9.
  • Olson M, Radhakrishnan SV, Luetkens T, et al. The role of surface molecule CD229 in multiple myeloma. Clin Immunol. 2019;204:69–73.
  • Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383–395.
  • Karlsson C, Baudet A, Miharada N, et al. Identification of the chemokine CCL28 as a growth and survival factor for human hematopoietic stem and progenitor cells. Blood. 2013;121(19):3838–3842.
  • Muccio VE, Saraci E, Gilestro M, et al. Multiple myeloma: new surface antigens for the characterization of plasma cells in the era of novel agents. Cytometry B Clin Cytom. 2016;90(1):81–90.
  • Nassar A, Radhakrishnan A, Cabrero IA, et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18(5):433–441.
  • Pascal LE, True LD, Campbell DS, et al. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics. 2008;9:246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.